Search hospitals
>
Florida
>
Miami
University of Miami Miller School of Medicine-Sylvester Cancer Center
Claim this profile
Miami, Florida 33136
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Brain Tumor
Conducts research for Lymphoma
793 reported clinical trials
85 medical researchers
Summary
University of Miami Miller School of Medicine-Sylvester Cancer Center is a medical facility located in Miami, Florida. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Brain Tumor, Lymphoma and other specialties. University of Miami Miller School of Medicine-Sylvester Cancer Center is involved with conducting 793 clinical trials across 813 conditions. There are 85 research doctors associated with this hospital, such as Julio C Barredo, MD, Jose Lutzky, MD, Chukwuemeka (Emeka) V. Ikpeazu, and Macarena I. De La Fuente.
Area of expertise
Cancer
University of Miami Miller School of Medicine-Sylvester Cancer Center has run 136 trials for Cancer. Some of their research focus areas include:
Lung Cancer
University of Miami Miller School of Medicine-Sylvester Cancer Center has run 90 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Julio C Barredo, MD
University of Miami Miller School of Medicine-Sylvester Cancer Center
8 years of reported clinical research
Jose Lutzky, MD
University of Miami
5 years of reported clinical research
Chukwuemeka (Emeka) V. Ikpeazu
University of Miami Miller School of Medicine-Sylvester Cancer Center
2 years of reported clinical research
Macarena I. De La Fuente
University of Miami Miller School of Medicine-Sylvester Cancer Center
6 years of reported clinical research
Clinical Trials running at University of Miami Miller School of Medicine-Sylvester Cancer Center
Cancer
Skin Cancer
Lung Cancer
Prostate Cancer
Brain Tumor
Ovarian Cancer
Breast Cancer
Multiple Myeloma
Cervical Cancer
Pancreatic Cancer
Immunotherapy + Chemotherapy
for Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting
2 awards
Phase 3
10 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting
2 awards
Phase 3
12 criteria
Radiation Therapy
for Cancer with Bone Metastasis
This phase III trial compares the effect of adding radiation therapy to usual care on the occurrence of bone-related complications in cancer patients with high-risk bone metastases that are not causing symptoms (asymptomatic). High-risk bone metastases are defined by their location (including hip, shoulder, long bones, and certain levels of the spine), or size (2 cm or larger). These bone metastases appear to be at higher risk of complications such as fracture, spinal cord compression, and/or pain warranting surgery or radiation treatment. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. The total dose of radiation can be delivered in a single day or divided in smaller doses for up to 5 days of total treatment. Usual care for asymptomatic bone metastases may include drugs that prevent bone loss, in addition to the treatment for the primary cancer or observation (which means no treatment until symptoms appear). Evidence has shown that preventative radiation therapy may be effective in lowering the number of bone metastases-related complications, however, it is not known if this approach is superior to usual care. Adding radiation therapy to usual care may be more effective in preventing bone-related complications than usual care alone in cancer patients with asymptomatic high-risk bone metastases.
Recruiting
2 awards
Phase 3
7 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Miami Miller School of Medicine-Sylvester Cancer Center?
University of Miami Miller School of Medicine-Sylvester Cancer Center is a medical facility located in Miami, Florida. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Brain Tumor, Lymphoma and other specialties. University of Miami Miller School of Medicine-Sylvester Cancer Center is involved with conducting 793 clinical trials across 813 conditions. There are 85 research doctors associated with this hospital, such as Julio C Barredo, MD, Jose Lutzky, MD, Chukwuemeka (Emeka) V. Ikpeazu, and Macarena I. De La Fuente.
Where is University of Miami Miller School of Medicine-Sylvester Cancer Center located?
**University of Miami Miller School of Medicine-Sylvester Cancer Center** - **Address:** 1475 NW 12th Ave, Miami, FL 33136 - **Hours:** Monday to Friday, 8:00 a.m. - 5:00 p.m. - **Transportation:** Accessible by driving, public transportation, or the UHealth shuttle service.
Who should I call to ask about financial aid or insurance network?
**University of Miami Miller School of Medicine Financial Assistance:** - For scholarships, grants, and loans, contact the Office of Financial Assistance at **305-243-2900** or visit their website. **Sylvester Comprehensive Cancer Center Insurance Inquiries:** - For insurance-related questions, call **305-689-7079** or check the insurance plans accepted page for coverage details.
What insurance does University of Miami Miller School of Medicine-Sylvester Cancer Center accept?
The University of Miami Miller School of Medicine-Sylvester Cancer Center accepts the Aetna Student Health insurance plan, mandatory for international students and optional for domestic students with the possibility to waive it for adequate personal coverage. The plan includes dental coverage within Florida and limited emergency dental care outside Florida; students must use a Florida address to enroll and select a Primary Care Dentist (PCD). Additionally, optional Vision Coverage is available through Aetna Vision Preferred, and Aetna is the primary behavioral health administrator, with Carisk included in a pilot program for enhanced mental and behavioral health services access.
What awards or recognition has University of Miami Miller School of Medicine-Sylvester Cancer Center received?
The University of Miami Miller School of Medicine-Sylvester Cancer Center collaborates with Moffitt Cancer Center and the University of Florida Health Cancer Center, receiving a $16,000 community grant for cancer detection and prevention. It benefits from multiple projects funded by the National Cancer Institute and other external agencies, including pharmaceutical companies. Additionally, the center provides internal awards like Dean's NIH Bridge grants, Research Support Awards, and a Grant Editing Support Program to bolster faculty research.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.